Moviprep (Ascorbic Acid, Sodium Ascorbate, Potassium Chloride, Sodium Chloride, Sodium Sulfate Anhydrous, Macr)

The polyethylene glycol polymer in Moviprep is not absorbed from the gut. It creates an iso‑osmotic solution together with electrolytes and ascorbic acid, drawing water into the intestinal lumen. The increased fluid softens stool and stimulates peristalsis, resulting in rapid evacuation of colonic contents.

The exact dose and dosing schedule of Moviprep are determined by the prescribing clinician based on the specific procedure, patient weight, renal function and other clinical factors. No universal dosing regimen is provided; the prescriber tailors the regimen to each individual.

Safety data for Moviprep in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and only under medical supervision.

To request Moviprep, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Moviprep combines polyethylene glycol with ascorbic acid, offering an iso‑osmotic, electrolyte‑balanced solution that tends to be better tolerated than some high‑volume PEG‑only preparations. Compared with sodium‑picosulfate regimens, Moviprep generally provides more predictable cleansing but may require a larger fluid intake.

Moviprep should be stored at ambient temperature, below 25 °C, in its original container. Protect the solution from moisture, direct sunlight and extreme temperatures. Do not freeze the product, and keep the container tightly sealed when not in use.

Moviprep is taken orally as a liquid solution. The prescribed volume is usually mixed with a specified amount of water, consumed according to the schedule provided by the prescriber, which often includes a split‑dose regimen on the day before the procedure.

The most serious risks include severe dehydration, marked electrolyte disturbances such as hyponatremia or hypokalemia, acute kidney injury, and, rarely, allergic reactions or colonic perforation. Patients should be monitored for signs of these complications, especially if they have underlying renal or cardiac disease.

Moviprep is contraindicated in patients with known hypersensitivity to any of its components, in those with severe renal impairment, uncontrolled electrolyte abnormalities, or in individuals for whom large fluid volumes are contraindicated. Pediatric use is not recommended without specific medical guidance.